Page last updated: 2024-12-07

ethylphenylpropiolate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethylphenylpropiolate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91516
CHEMBL ID1992423
SCHEMBL ID852513
MeSH IDM0064298

Synonyms (57)

Synonym
ethylphenylpropiolate
ethyl phenylpropiolate
ethyl phenylpropriolate
ethyl 3-phenylpropiolate
nsc41566
nsc-41566
ethyl phenylacetylenecarboxylate
phenylacetylene monocarboxylic acid ethyl ester
NCI60_003943
ccris 4504
ethyl 3-phenyl-2-propynoate
ethyl 3-phenylpropynoate
nsc 41566
ethyl phenylpropynoate
ai3-04344
einecs 218-703-8
propiolic acid, phenyl-, ethyl ester
brn 0639637
ethyl 3-phenylprop-2-ynoate
inchi=1/c11h10o2/c1-2-13-11(12)9-8-10-6-4-3-5-7-10/h3-7h,2h2,1h
2216-94-6
2-propynoic acid, 3-phenyl-, ethyl ester
ethyl phenylpropiolate, 98%
P-4210
phenylpropiolic acid ethyl ester
phenylpropargylic acid ethyl ester
ethyl phenylpropargylate
P0814
AKOS007930276
3-phenyl-prop-2-ynoic acid ethyl ester
unii-09cyb3z9mr
4-09-00-02328 (beilstein handbook reference)
09cyb3z9mr ,
FT-0625789
ethyl 2-phenylacetylenecarboxylate
3-phenyl-2-propynoic acid ethyl ester
ethyl 3-phenylpropargylate
SCHEMBL852513
3-phenylpropynic acid ethyl ester
phenyl-propynoic acid ethyl ester
phenylacetylenecarboxylic acid ethyl ester
phenyl propynoic acid ethyl ester
CHEMBL1992423
ethyl 3-phenyl-2-propynoate #
DTXSID9074858
mfcd00009185
AS-58137
F0001-0782
ethylphenylpropalate
SY010778
CS-0066796
Q26841274
ethyl-3-phenylpropiolate
W18306
EN300-214661
?ethyl phenylpropiolate
PD168605

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Differences in time courses of the responses which were not altered by experimentally varying rate of absorption and in components of the inflammatory response to the three irritants suggest that chemicals induce skin irritation by multiple mechanisms."( Mechanisms of chemically induced skin irritation. I. Studies of time course, dose response, and components of inflammation in the laboratory mouse.
Burkhalter, A; Maibach, HI; Patrick, E, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1432755Competitive inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production preincubated with enzyme followed by addition of varying levels of urea as substrate measured for 120 mins by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1687065Inhibition of Escherichia coli MurA assessed as residual activity at 100 uM using UNAG and PEP as substrate preincubated for 30 mins in presence of UNAG followed by PEP addition and measured after 15 mins by malachite green colorimetric assay relative to 2018European journal of medicinal chemistry, Dec-05, Volume: 160A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
AID1687066Inhibition of Escherichia coli MurA assessed as residual activity at 100 uM using UNAG and PEP as substrate preincubated for 30 mins in presence of UNAG followed by PEP addition and measured after 15 mins in presence of 5 mM cysteine by malachite green co2018European journal of medicinal chemistry, Dec-05, Volume: 160A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
AID1687067Inhibition of recombinant cathepsin B (unknown origin) endopeptidase activity expressed in Escherichia coli assessed as residual activity at 100 uM using Z-RR-AMC as substrate preincubated for 30 mins under shaking in presence of 5 mM cysteine followed by2018European journal of medicinal chemistry, Dec-05, Volume: 160A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
AID1687069Inhibition of recombinant cathepsin X (unknown origin) expressed in Pichia pastoris assessed as residual activity at 100 uM using Abz-Fek(Dnp)-OH as substrate preincubated for 30 mins under shaking in presence of 5 mM cysteine followed by substrate additi2018European journal of medicinal chemistry, Dec-05, Volume: 160A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
AID1432759Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring initial state enzyme-inhibitor complex using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432754Time-dependent Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production using urea as substrate by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1687064Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli assessed as residual activity at 100 uM using UNAG and PEP as substrate preincubated for 30 mins in presence of UNAG followed by PEP addition and measured after 15 mins by malachite gr2018European journal of medicinal chemistry, Dec-05, Volume: 160A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
AID1687068Inhibition of recombinant cathepsin B (unknown origin) exopeptidase activity expressed in Escherichia coli assessed as residual activity at 100 uM using Abz-GIVRAK(Dnp)-OH as substrate preincubated for 30 mins under shaking in presence of 5 mM cysteine fo2018European journal of medicinal chemistry, Dec-05, Volume: 160A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
AID1432751Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432756Reversible inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring recovery of enzyme activity at 10 times IC50 preincubated for 60 mins followed by 100-fold dilution in to PBS containing urea as subst2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432760Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring steady state enzyme-inhibitor complex using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (43.33)18.7374
1990's10 (33.33)18.2507
2000's3 (10.00)29.6817
2010's4 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.00 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]